Continues to build patent portfolio and strengthen protection for antipsychotic transdermal program following completion of proof of concept clinical trials
VANCOUVER, BC. October 10th, 2017 - Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“ Aequus ” or the “Company”), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, announced today that the State Intellectual Property Office of the People’s Republic of China (SIPO) has granted a Chinese patent for Aequus’ once-weekly transdermal patch containing aripiprazole, in development for the treatment of certain psychiatric disorders. The patent, granted under No. 201180052667.0, is titled “Aripiprazole compositions and methods for its transdermal delivery”. This patent has been granted in six other major countries or regions, including the US, Russia, Mexico, Japan, Canada and Australia, and is pending in multiple additional territories.
“We continue to globally expand and strengthen our patent portfolio for our once-weekly transdermal aripiprazole program,” said Anne Stevens, COO and Director of Aequus Pharmaceuticals. “This Chinese patent not only secures key elements of our formulation in a significant market, it also expands regional out-licensing and partnering opportunities. This comes at an important time as we accelerate our business development efforts for this program, a key initiative for increasing shareholder value.”
Aequus owns worldwide rights to the formulation described in the issued patent.
Aripiprazole is an atypical anti-psychotic sold as a once daily, oral tablet under the brand name Abilify ®. Originally approved and marketed in 2002 for schizophrenia, Abilify ® is currently sold in over 65 countries and regions. Since its initial approval, aripiprazole has seen a label expansion in the United States to include acute treatment of manic and mixed episodes associated with bipolar I, adjunctive treatment of major depressive disorder, irritability associated with autistic disorder, and treatment of Tourette’s disorder. Although Abilify ® is a market leader in the US, Aequus believes it has limitations due to its daily dosing regimen which is associated with a high rate of non-adherence and relapse. Aequus’ proposed transdermal, once-weekly aripiprazole patch is designed to consistently deliver aripiprazole over a seven-day period at levels comparable to currently marketed once-daily formulations. By delivering aripiprazole over seven days in a comfortable, convenient and easy-to-use weekly patch, AQS-1301 is intended to promote enhanced patient compliance.
About Aequus Pharmaceuticals
Aequus Pharmaceuticals Inc. (TSX-V:AQS,OTCQB: AQSZF)is a growing specialty pharmaceutical company focused on developing and commercializing high quality, differentiated products. Aequus’ development stage pipeline includes several products in neurology and psychiatry with a goal of addressing the need for improved medication adherence through enhanced delivery systems. With a focus in neurology and other specialty areas, our most recent addition to the development pipeline was a long-acting form of medical cannabis, where there is a high need for a consistent, predictable and pharmaceutical-grade delivery of products for patients. Aequus intends to commercialize its internal programs in Canada alongside its current portfolio of marketed established medicines and will look to form strategic partnerships that would maximize the reach of its product candidates worldwide. Aequus plans to build on its Canadian commercial platform through the launch of additional products that are either created internally or brought in through an acquisition or license; remaining focused on highly specialized therapeutic areas. For further information, please visit www.aequuspharma.ca